| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Division of Medical Oncology, Department of Medicine, University of Washington Medical Center, and the Fred Hutchinson Research Center, Seattle
Study objective: To determine the efficacy of methotrexate, vinblastine, and platinum chemotherapy in patients with diffuse unresectable malignant mesothelioma.
Design: Patients with histologically confirmed malignant mesothelioma were evaluated for treatment with methotrexate, vinblastine, and cisplatin chemotherapy. If the patient had preexisting hearing loss or neuropathy, or was significantly disabled (eg, spending greater than half of the day in bed or a chair), cisplatin therapy was withheld.
Setting: All patients were initially evaluated at the University of Washington Medical Center and received chemotherapy at the University of Washington or in the community.
Interventions: Between 1990 and 1994, 17 patients received this chemotherapy. Ten patients received cisplatin, 100 mg/m2 IV on day 1, methotrexate, 30 mg/m2 IV on days 8, 15, and 22, and vinblastine, 3 mg/m2 IV on days 8, 15, and 22, in 28-day cycles. One patient had carboplatin substituted for cisplatin due to preexisting hearing loss. Six patients received weekly methotrexate and vinblastine at the same doses without platinum.
Measurements and results: Nine of the 17 (53%; 95% confidence interval [CI], 28 to 77%) patients responded, including two complete remissions, two partial remissions, and five regressions. Median time to progression is 8 months. The median survival time for all patients is 14 months. Projected 2-year survival is 35% (95% CI, 12 to 60%).
Conclusions: Although the number of the patients in this study is small, the response rate and projected 2-year survival of 35% are better than those typically reported for unresectable malignant mesothelioma. Further investigation is warranted in confirmatory trials.
Key Words: carboplatin • chemotherapy • cisplatin • mesothelioma • methotrexate • vinblastine
Submitted on July 26, 1995
Accepted on November 3, 2007
This article has been cited by other articles:
|
|
 |
|
  A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. V Boddy, M. Verrill, et al. Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., August 15, 2002; 20(16): 3533 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aziz, A. Jilaihawi, and D. Prakash The management of malignant pleural mesothelioma; single centre experience in 10 years Eur. J. Cardiothorac. Surg., August 1, 2002; 22(2): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Butchart Contemporary Management of Malignant Pleural Mesothelioma Oncologist, December 1, 1999; 4(6): 488 - 500. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Metintas, N. Ozdemir, I. Ucgun, O. Elbek, M. Kolsuz, S. Mutlu, and S. Metintas Cisplatin, Mitomycin, and Interferon-{alpha}2a Combination Chemoimmunotherapy in the Treatment of Diffuse Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 391 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Campbell Malignant Mesothelioma Ann. Thorac. Surg., May 1, 1997; 63(5): 1503 - 1505. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
